Gilead's Kite Announced New Analysis Showing Second-Line Yescarta Provides Consistent Benefit In R/R LBCL Patients, Including Those Ineligible For High-Dose Chemotherapy And ASCT

 Kite, a Gilead Company (NASDAQ:GILD), presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), even among those ineligible for the previous standard of care, high-dose chemotherapy followed by an autologous stem cell transplant (ASCT).